| Autor: |
Kosmidis, J., Giamarellou, H., Papadakis, M., Eliades, E., Daikos, G. K. |
| Předmět: |
|
| Zdroj: |
Journal of Antimicrobial Chemotherapy (JAC); Mar1983, Vol. 11 Issue 3, p239-244, 6p |
| Abstrakt: |
Two regimes of rifaprim (RPM), a 3.75 to 1 combination of rifampicin (RIF) and trimethoprim (TMP), were compared with co–-trimoxazole (CO-T) for the treatment of urinary tract infection in 60 patients. Dosages were: A, 450 mg RIF+ 120 mg TMP twice daily; B, 600 mg RJF+160mg TMP at bedtime and C, 800 mg sulphamethoxazole (SMZ)+ 160 mg TMP twice daily. Clinical results were similar but CO-T treatment was accompanied by a greater number of late bacteriological failures. In none of 40 patients receiving RPM did resistance to any of the components develop, while in three of 20 patients receiving CO–T resistance to TMP or SMZ emerged during treatment. There were no side effects in the patients receiving RPM, but three patients developed transient laboratory abnormalities. One patient receiving CO-T had a rash and one further transient laboratory abnormalities. Satisfactory concentrations of RIF and TMP were measured in urine up to 24 h after a dose of 600 mgRIF+160mgTMP. RIF may be a better companion to TMP than the sulphonamides for the treatment of urinary tract infection. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
